The impact of remission status on patients’ experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data
Shared decision-making in acute myeloid leukemia (AML) requires understanding patients’ longitudinal experiences of illness, but little is known about the impact of remission status on patient-reported outcomes (PROs). We aimed to explore the association between remission status and PROs 6–12 months following induction chemotherapy.
Forty-two patients completed three validated instruments characterizing symptom burden (Patient Care Monitor v2.0), distress (NCCN Distress Thermometer), and QOL (FACT-Leu), as part of a longitudinal observational study. We used regression models to explore the relationship between remission status and PROs, and explore differences by initial disease type (de novo versus secondary/relapsed AML).
Those with secondary or relapsed AML at study onset had marked impairments in all measures compared to de novo AML patients. After 6 months, their mean distress score was 4.8 (> 4.0 warrants intervention), they reported a mean of 14.1 moderate/severe symptoms and had a mean QOL score of 113.6, compared to 1.0, 1.7, and 155.2, respectively, for those with de novo AML (p < .0001). Similarly, patients in relapse had a mean distress score of 5.3, a mean of 12.8 moderate/severe symptoms, and a mean QOL score of 113.4, compared to 1.8, 5.7, and 143.8, respectively, among those in remission (p < .005). These patterns persisted after adjusting for baseline differences (p < .0001).
Remission is associated with markedly better patient well-being in AML. Patients with secondary or relapsed AML face more severe symptom burden, distress, and QOL issues after induction. Interventions are needed to improve AML patients’ experiences of illness.
KeywordsAcute myeloid leukemia Quality of life Distress Symptom burden Remission Patient-reported outcomes
Compliance with ethical standards
The Institutional Review Board of the Duke University School of Medicine approved this protocol. Informed consent was obtained from all individual participants included in the study.
Conflicts of interest
The authors declare that they have no relevant conflicts of interest.
- 1.Acute Myeloid Leukemia - Cancer Stat Facts, National Cancer Institute- SEER (2017) [Online]. Available: https://seer.cancer.gov/statfacts/html/amyl.html. Accessed: 23-May-2017
- 3.Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 106(5):1090–1098. https://doi.org/10.1002/cncr.21723 CrossRefPubMedGoogle Scholar
- 5.Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358(18):1909–1918. https://doi.org/10.1056/NEJMoa074306 CrossRefPubMedGoogle Scholar
- 7.LeBlanc TW, Fish LJ, Bloom CT, El-Jawahri A, Davis DM, Locke SC, Steinhauser KE, Pollak KI (2016) Patient experiences of acute myeloid leukemia: a qualitative study about diagnosis, illness understanding, and treatment decision-making. Psychooncology. https://doi.org/10.1002/pon.4309
- 12.Alibhai S et al (2015) Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. J Geriatr Oncol 6(4 // 6220–12 (LLS) *Canadian Institutes of Health Research* // 86697 (CIHR) *Canadian Institutes of Health Research*):262–271CrossRefPubMedGoogle Scholar
- 14.Sekeres MA et al (2004) Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leuk Off J Leuk Soc Am Leuk Res Fund UK 18(4):809–816Google Scholar
- 16.LeBlanc TW and El-Jawahri A (2015) When and why should patients with hematologic malignancies see a palliative care specialist?, In: American society of hematology education program, vol. 2015, no. 1, pp. 471–478Google Scholar
- 17.El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, Jackson VA, Telles J, Rhodes A, Spitzer TR, McAfee S, Chen YBA, Lee SS, Temel JS (Nov. 2016) Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA 316(20):2094–2103. https://doi.org/10.1001/jama.2016.16786 CrossRefPubMedCentralPubMedGoogle Scholar
- 18.LeBlanc TW (2017) Advance care planning and palliative care specialists in malignant hematology and stem-cell transplantation: on why it takes a village. J Oncol Pract, vol. JOP2017026. https://doi.org/10.1200/JOP.2017.026930
- 21.Loggers ET, LeBlanc TW, El-Jawahri A, Fihn J, Bumpus M, David J, Horak P, Lee SJ (2016) Pretransplantation supportive and palliative care consultation for high-risk hematopoietic cell transplantation patients. Biol Blood Marrow Transplant 22(7):1299–1305. https://doi.org/10.1016/j.bbmt.2016.03.006 CrossRefPubMedGoogle Scholar
- 23.Abernethy AP, Herndon JE II, Wheeler JL, Day JM, Hood L, Patwardhan M, Shaw H, Lyerly HK (2009) Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. J Pain Symptom Manag 37(6):1027–1038. https://doi.org/10.1016/j.jpainsymman.2008.07.011 CrossRefGoogle Scholar
- 24.Abernethy AP, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE II (2010) Validation of the patient care monitor (version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manag 40(4):545–558. https://doi.org/10.1016/j.jpainsymman.2010.01.017 CrossRefGoogle Scholar
- 28.Cella D et al (2012) Measuring health-related quality of life in leukemia: the functional assessment of cancer therapy—Leukemia (FACT-Leu) questionnaire. Value Heal 15(8)Google Scholar
- 29.Cella D, Tulsky D, Gray G (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Densitom 11:570–579Google Scholar
- 31.NCCN (2014) NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. [Online]. Available: http://williams.medicine.wisc.edu/aml.pdf. Accessed: 05-Jun-2017
- 32.Wang C-W, Chow AY, and Chan CL (2017) The effects of life review interventions on spiritual well-being, psychological distress, and quality of life in patients with terminal or advanced cancer: a systematic review and meta-analysis of randomized controlled trials. Palliat Med, p. 26921631770510. https://doi.org/10.1177/0269216317705101
- 33.Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner R (2013) Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol 31(6):782–793. https://doi.org/10.1200/JCO.2011.40.8922 CrossRefPubMedGoogle Scholar
- 35.Alibhai SMH, Durbano S, Breunis H, Brandwein JM, Timilshina N, Tomlinson GA, Oh PI, Culos-Reed SN (Nov. 2015) A phase II exercise randomized controlled trial for patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Res 39(11):1178–1186. https://doi.org/10.1016/j.leukres.2015.08.012 CrossRefGoogle Scholar